Skip to content

Dietary treatment of children with Angelman Syndrome and refractory epilepsy

Dietary treatment of children with Angelman Syndrome and refractory epilepsy - Dietary treatment in Angelman Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON43592
Enrollment
20
Registered
2016-05-03
Start date
2016-03-01
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angelman Syndrome

Interventions

During study patients use adequately dosed AED in depended to kind of study group. First period: After a run-in period of 1 month in which patients follow normal diet and AED will be continued and
3 months Randomisation into 1. Diet group: KD (5 energy% carbohydrates), containing 15 energy% MCT fat and AED. 2. Control group: continue normal diet (patient related) . Third period: 3 months 1.
- patients with > 50 % seizure reduction switch to a MAD (10 energy % range 20-40 grams carbohydrates ), energy from fat and protein is unrestricted, 15 energy% MCT fat supplemented. - patients w

Sponsors

KInderneurologie
Lead Sponsor

Eligibility

Age
2 Years to 17 Years

Inclusion criteria

Inclusion criteria: - Angelman syndrome (genetically proven) - > 2 year - 50% of energy need by oral food. - Written informed consent by parents - AED use

Exclusion criteria

Exclusion criteria: - 18 years. - on KD or LGID treatment during the past 6 months. - overweight: weight /height : > +2.5 SD or BMI >30 - underweight : weight/height; 50% of energy need) tube feeding dependent. - deviated lipid profiles

Design outcomes

Primary

MeasureTime frame
- 50% seizure reduction or more after 3 months of dietary treatment.

Secondary

MeasureTime frame
-observation of level of ketosis during dietary treatment. ketosis will be measured on daily basis by parents -improved EEG outcomes. -maintaining or improved QoL. -maintaining patient related growth curves. -safety by closely monitoring of side effects of AED and dietary treatment. -feasibility by monitoring behavior, feeding difficulties and parental stress by questionnaires . -protocol compliance.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)